Finer Market Points: ASX Top 10 Momentum Stocks: 26 Feb 2024 NASDAQ:PAA ASX:BRN MIL:BRE ASX:RIM ASX:DRO NYSE:FND GETTEX:STP NASDAQ:BVS ASX:RDM
Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list.
The Launch Pad List is published weekly on Fridays.
Today's ASX's Top 10 Quarterly Momentum Stocks are:
Pharmaust Limited (PAA)
Brainchip Ltd (BRN)
Brazilian Rare Earth (BRE)
Rimfire Pacific (RIM)
Droneshield Limited (DRO)
Findi Limited (FND)
Step One Limited (STP)
Bravura Solution Ltd (BVS)
Red Metal Limited (RDM)
ECQ trade ideas
Finer Market Points: ASX Top 10 Momentum Stocks: 15 Feb 2024NYSE:ARR MIL:BRE ASX:RIM ASX:BRN ASX:ACW ASX:RDM GETTEX:CXU EURONEXT:CTT NASDAQ:PAA
Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list.
The Launch Pad List is published weekly on Fridays.
Today's ASX's Top 10 Quarterly Momentum Stocks are:
American Rare Earths Limited (ARR)
Brazilian Rare Earths Limited (BRE)
Rimfire Pacific Mining Limited (RIM)
Brainchip Holdings Ltd (BRN)
Actinogen Medical Limited (ACW)
Red Metal Limited (RDM)
Cauldron Energy Limited (CXU)
Cettire Limited (CTT)
Pharmaust Limited (PAA)
Droneshield Limited (DRO)
PAA - Trade PlanPAA is trading currently n a descending wedge and is struggling to close above long term trendline. If it manages to close in the given spot (Green Circle Buy Zone), then it may confirm a change in trend and may get bullish, as this is a very Bullish structure. We need to see good volume and a thrust to the upside for confidence. Lets see how it develops in the upcoming sessions.
Please note these are my own notes, by no means trading advice. Please do your own research before entering into any trade.
$PAA - doggy spec biotech basing up. after the pump through 19 recently this thing has come back and tested support. Id suggest clearly not being bought up by funds. However, looking much better for a test of resistance on the hourly at 22.5c.
From the recent presentation, the next move was to test their drug against human lung tissue to test its impact on covid infected cells.
$PAA wanted to see the break of May 12 high and close above.This is a biostock so, very high risk play. Been looking/waiting for the move above the May 12 high of 17.5c. Lets see how they close it this week. Their drug appears to be effective in suppressing the covid virus in cell culture. Human safety already achieved, so awaiting phase 1 trials.
$PAA:ASX - PHARMAUST - Up 170% over the last 3 monthsPharmAust is a clinical-stage company developing targeted cancer therapeutics for both humans and animals through re-purposing marketed drugs lowering the risks and costs of development. They look to have broken through a previous resistance area and could be worth a watch.
Current demand shows 76 buyers for 3,015,228 units with only 19 sellers for 2,181,188 units.
The principal activities of the Company are to develop its own drug discovery intellectual property, namely approximately three platforms for the treatment of different types of cancers in humans and animals, as well as providing specialized medicinal and synthetic chemistry services on a contract basis to clients. The Company's segments are Corporate and Pharmaceutical. The Pharmaceutical segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The Corporate segment covers all the corporate overhead expenses. Its subsidiaries include Pitney Pharmaceuticals Pty Ltd, which is engaged in business of developing therapeutic cancer products, and Epichem Pty Ltd, which offers a range of rare and hard to find pharmaceutical impurities, degradants and metabolites of active ingredients and excipients, particularly for over-the-counter and generic drugs.
